our Premium Content: News alerts, weekly reports and conference planners

GENE:

TOP2A (DNA topoisomerase 2-alpha)

News alerts, weekly reports and conference planners

Integrative Bioinformatics and Experimental Validation Establish CCNB1 as a Potential Biomarker for Diagnosis and Prognosis in Colorectal Cancer. (PubMed, Curr Issues Mol Biol)

In vitro, CCNB1 knockdown triggered cell cycle arrest, thereby suppressing the proliferation of colorectal cancer cells. This study validated CCNB1 as a dual-purpose biomarker for CRC diagnosis and favorable prognosis, highlighting its potential utility in clinical management.

4 days ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • CDCA3 (Cell Division Cycle Associated 3) • CCNA2 (Cyclin A2) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • CDC20 (Cell Division Cycle 20) • KIF11 (Kinesin Family Member 11) • MCM4 (Minichromosome Maintenance Complex Component 4) • CCNB1 (Cyclin B1) • CDK3 (Cyclin Dependent Kinase 3) • CEP55 (Centrosomal Protein 55) • CKS2 (CDC28 Protein Kinase Regulatory Subunit 2) • CRYAB (Crystallin Alpha B) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • MMP3 (Matrix metallopeptidase 3) • TPM2 (Tropomyosin 2) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)

Molecularly Imprinted Polymer Nanoparticles for Lung-Cancer-Cell-Surface Proteomics. (PubMed, Polymers (Basel))

Among these hub proteins, five proteins (NPM1, TOP2A, EZH2, PRKDC, and HNRNPK) were identified as clinically relevant when cross-referenced with the Human Protein Atlas database and the literature, highlighting their potential as diagnostic and therapeutic targets. These findings highlight the potential of nanoMIP-based snapshot imprinting as an alternative to 'classical' approaches for identifying potential protein targets for diagnostic and therapeutic applications.

6 days ago

Journal

NPM1 (Nucleophosmin 1) • TOP2A (DNA topoisomerase 2-alpha) • HNRNPK (Heterogeneous Nuclear Ribonucleoprotein K) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)

12d

Phosphoproteome landscape of ARID1A and its implications in DNA damage response and breast cancer pathogenesis. (PubMed, Discov Oncol)

This study enhances our understanding of ARID1A regulatory mechanisms, highlighting its phosphorylation as a key driver of breast cancer biology. Future research should validate these kinase-substrate interactions and explore their transcriptional and chromatin-level impacts to develop precision therapies for ARID1A-dysregulated cancers.

12 days ago

Journal

ER (Estrogen receptor) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • TOP2A (DNA topoisomerase 2-alpha) • CHEK2 (Checkpoint kinase 2) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • BRD4 (Bromodomain Containing 4) • TP53BP1 (Tumor Protein P53 Binding Protein 1) • MAPK14 (Mitogen-Activated Protein Kinase 14) • MAPK9 (Mitogen-Activated Protein Kinase 9)

13d

Transcriptomics driven identification of hub gene miRNA interactions for biomarker and therapeutic target discovery in gynecological cancers. (PubMed, Front Oncol)

The identified miRNAs exhibit strong regulatory interactions with these hub genes, while serine/threonine protein kinases emerged as the most significantly associated group. Together, these findings highlight promising biomarker candidates and potential therapeutic targets for gynecological cancers.

13 days ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • BIRC5 (Baculoviral IAP repeat containing 5) • AURKA (Aurora kinase A) • TGFB1 (Transforming Growth Factor Beta 1) • CCNB2 (Cyclin B2) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • MIR381 (MicroRNA 381) • MIR495 (MicroRNA 495) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CCNB1 (Cyclin B1) • CDCA8 (Cell Division Cycle Associated 8) • MIR653 (MicroRNA 653)

15d

Action mechanism of Qianlie Xiaozheng decoction against prostate cancer: network pharmacology, molecular docking, and molecular dynamics simulations. (PubMed, Comput Methods Biomech Biomed Engin)

Molecular dynamics simulations supported baicalein-TOP2A complex stability. These findings reveal QLXZD exerts anti-PCa effects via a multi-component, multi-target mechanism, supporting its clinical application.

15 days ago

Journal

EGFR (Epidermal growth factor receptor) • TOP2A (DNA topoisomerase 2-alpha) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)

15d

Lymph Node Metastasis-Associated Spatiotemporal Mapping of the TFF3-Linked Niche in Breast Cancer: Integrating Radiogenomic Signatures with Immune-Ecosystem Remodeling. (PubMed, Research (Wash D C))

Furthermore, the antimigratory effect of 6-mercaptopurine was reversed by TFF3 overexpression, confirming the functional specificity of this drug-target interaction. Notably, tumors with high TFF3 expression (TFF3hi) exhibited elevated resistance to PD-1 inhibitors but heightened sensitivity to MAPK inhibitors, suggesting a potential theranostic framework for ALNM stratification.

15 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • TOP2A (DNA topoisomerase 2-alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • GZMA (Granzyme A) • TFF3 (Trefoil factor 3)

mercaptopurine

18d

Integrated Network Analysis Reveals a Directly Regulatory Network of FOXM1 Associated With the Cell Cycle in Lung Adenocarcinoma. (PubMed, Bioinform Biol Insights)

The predicted regulatory network of FOXM1 shows significant discrepancies with experimental validation data. Therefore, FOXM1's regulatory role in the cell cycle requires further experimental verification.

18 days ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • FOXM1 (Forkhead Box M1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • CENPF (Centromere Protein F) • KIF20A (Kinesin Family Member 20A)

19d

The non-metabolic role of MTHFD2 in regulating mitochondrial fission-dependent mitophagy via stabilizing TOP2A mRNA in glioblastoma. (PubMed, Free Radic Biol Med)

In conclusion, we proposed a non-canonical function of MTHFD2, which bound to and stabilized the mRNA of TOP2A. Targeting MTHFD2 triggered excessive mitophagy and cell apoptosis in GBM via destabilizing TOP2A mRNA.

19 days ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • MTHFD2 (Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 2)

20d

Using transcriptomics and molecular docking to uncover the pharmacological targets and its associated biological mechanisms of paeoniflorigenone in treating bladder cancer. (PubMed, Discov Oncol)

It was initially discovered that PAG exerts its therapeutic effects on bladder cancer by targeting multiple pathways and multiple targets. This finding will enhance our comprehension of the potential mechanism by which PAG combats bladder cancer, and it will serve as a theoretical foundation for future research endeavors.

20 days ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • IL17A (Interleukin 17A) • MMP9 (Matrix metallopeptidase 9) • MMP1 (Matrix metallopeptidase 1) • PRSS1 (Serine Protease 1) • MMP14 (Matrix Metallopeptidase 14) • MMP7 (Matrix metallopeptidase 7)

24d

Differentially Expressed Genes Associated with the Development of Cervical Cancer. (PubMed, Int J Mol Sci)

The publicly available microarray datasets, including GSE39001, GSE9750, GSE7803, GSE6791, GSE63514, and GSE52903 in combination with bioinformatics database predictions, were used to identify differential expression genes, potential biomarkers, and therapeutic targets for cervical cancer; additionally, we undertook bioinformatic analysis to determine gene ontology and possible miRNA targets related to our DEGs...Interestingly, hub proteins KIF4A, NUSAP1, BUB1B, CEP55, DLGAP5, NCAPG, CDK1, MELK, KIF11, and KIF20A were found to be potentially regulated by several miRNAs, including miR-107, miR-124-3p, miR-147a, miR-16-5p, miR-34a-5p, miR-34c-5p, miR-126-3p, miR-10b-5p, miR-23b-3p, miR-200b-3p, miR-138-5p, miR-203a-3p, miR-214-3p, and let-7b-5p. The relationship between these genes highlights their potential as candidate biomarkers for further research in treatment, diagnosis, and prognosis.

24 days ago

Journal

TP53 (Tumor protein P53) • TOP2A (DNA topoisomerase 2-alpha) • RAD51 (RAD51 Homolog A) • MIR200B (MicroRNA 200b) • MIR34A (MicroRNA 34a-5p) • RAD51AP1 (RAD51 Associated Protein 1) • NUSAP1 (Nucleolar and Spindle Associated Protein 1) • ELF3 (E74 Like ETS Transcription Factor 3) • FOXM1 (Forkhead Box M1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • MIR126 (MicroRNA 126) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • NCAPG (Non-SMC Condensin I Complex Subunit G) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CEP55 (Centrosomal Protein 55) • CXCL14 (C-X-C Motif Chemokine Ligand 14) • E2F1 (E2F transcription factor 1) • KIF20A (Kinesin Family Member 20A) • KIF4A (Kinesin Family Member 4A) • MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • MIR10B (MicroRNA 10b) • MIR138 (MicroRNA 138) • MIR203A (MicroRNA 203a) • MIR214 (MicroRNA 214) • MIRLET7B (MicroRNA Let-7b) • RELA (RELA Proto-Oncogene) • RFC4 (Replication Factor C Subunit 4) • MIR124-3 (MicroRNA 124-3)

27d

Zeaxanthin targets TOP2A to regulate autophagy and suppress lung cancer progression via the MAPK/ERK pathway. (PubMed, Transl Oncol)

In vivo studies using an orthotopic LC model revealed that Zea treatment markedly reduced tumor growth, accompanied by decreased TOP2A and Ki67 expression. Collectively, our findings establish Zea as a potent LC therapeutic agent that suppresses tumor progression by targeting TOP2A, inhibiting the MAPK/ERK pathway, and ultimately modulating autophagy.

27 days ago

Journal

TOP2A (DNA topoisomerase 2-alpha)